Cargando…
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies
AIM: To evaluate the efficacy and safety of adjunct dapagliflozin therapy in patients with type 1 diabetes (T1D). MATERIALS AND METHODS: DEPICT‐1 and ‐2 were randomized, double‐blind, parallel‐group, 24‐week studies, with 28‐week extension periods. Adults with T1D and HbA1c 7.5%‐10.5% were randomize...
Autores principales: | Phillip, Moshe, Mathieu, Chantal, Lind, Marcus, Araki, Eiichi, di Bartolo, Paolo, Bergenstal, Richard, Heller, Simon, Hansen, Lars, Scheerer, Markus Florian, Thoren, Fredrik, Arya, Niki, Xu, John, Iqbal, Nayyar, Dandona, Paresh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839492/ https://www.ncbi.nlm.nih.gov/pubmed/33145944 http://dx.doi.org/10.1111/dom.14248 |
Ejemplares similares
-
Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial
por: Mathieu, Chantal, et al.
Publicado: (2020) -
Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021) -
SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019) -
Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)
por: Mathieu, Chantal, et al.
Publicado: (2020) -
Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial
por: Araki, Eiichi, et al.
Publicado: (2019)